Archives — January 2012 back to current month (2)
It may seem counterintuitive that rare diseases might actually be biotech growth drivers, but Senior Analyst and Managing Director Geoff Meacham of JPMorgan Chase makes just that case. In this exclusive interview with The Life Sciences Report, Meacham lays out his premise that hepatitis C and orphan disease drugs can cure the woes of growth-starved investors.
The 2012 Biotech Showcase investor conference in San Francisco drew a record number of life science interests from all over the world.
|"INO's pro forma cash position after the offering could be around $160M and should be sufficient for 18 months of operations; we reiterate our Buy rating."|
|"We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."|